A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
The company adds royalty aggregation to its R&D business.
